Chronic Myeloid Leukemia (CML) clinical trials

16 trials changed in the last 30 days: 0 stopped, 7 with notable changes, 9 with minor changes only.

1. Notable

   Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients…Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

   Primary completion pushed from Jul 2026 to Jun 2027

   Also in this update: Study completion pushed from Dec 2026 to Jun 2027

   Obafemi Awolowo University·Phase 2· NCT07022743· Registry history of NCT07022743 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

2. Notable

   PHARM-LMC · Interest of PHARMaceutical Conciliation to…PHARM-LMC · Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia

   Primary completion pushed from Nov 1, 2025 to Dec 31, 2027

   Also in this update: Study completion pushed from Nov 1, 2026 to Dec 31, 2028

   Centre Hospitalier Universitaire de Saint Etienne·Not applicable· NCT05130138· Registry history of NCT05130138 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

3. Notable

   CARDINAL · MK-4208/TERN-701 · Chronic Myeloid Leukemia (CML)…CARDINAL · MK-4208/TERN-701 · Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

   Primary endpoint(s) modified

   Also in this update: Enrollment increased: 180 → 330 participants; Interventions modified

   Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·Phase 1/2· NCT06163430· Registry history of NCT06163430 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

4. Notable

   ASTX727 and Dasatinib · Newly Diagnosed Philadelphia Chromosome…ASTX727 and Dasatinib · Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

   Primary and study completion pushed from Oct 30, 2026 to Oct 30, 2028

   M.D. Anderson Cancer Center·Phase 2· NCT05007873· Registry history of NCT05007873 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

5. Notable

   Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before…Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   Primary completion pushed from Sep 2026 to Sep 2027

   Also in this update: Study completion pushed from Mar 2027 to Mar 2028

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Early Phase 1· NCT06398457· Registry history of NCT06398457 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

6. Notable

   CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL…CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

   Study completion date changed from estimate of Dec 31, 2025 to Sep 8, 2026

   Also in this update: Trial completed

   Otsuka Beijing Research Institute·Phase 2· NCT04233346· Registry history of NCT04233346 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

7. Notable

   Asciminib · Newly Diagnosed Chronic Myeloid Leukemia in Chronic…Asciminib · Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

   Enrollment increased: 50 → 150 participants

   M.D. Anderson Cancer Center·Phase 2· NCT06236724· Registry history of NCT06236724 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.